U.Va. engineering professor’s novel cancer therapy moves to phase 1A clinical trials
By Brigitte Meyer | September 26, 2022Biomedical Engineering Prof. Kimberly Kelly and her team have pioneered a new antibody therapy for pancreatic cancer that is now in phase 1A dose escalation safety trial.